Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy

This article was originally published in Scrip

Executive Summary

Amgen Inc. made history on Oct. 27 by gaining the FDA's approval for the first oncolytic virus therapy – Imlygic (talimogene laherparepvec), which is indicated as a local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.


Related Content

R&D Head Sean Harper On Amgen's Long-Term Investment View
How To Get Ahead In The Trendy World Of Immuno-Oncology
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited
Immuno-Oncology's Next Wave: Key Targets And Emerging Players


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts